at least one ICD10 code (M300, M301, M313, or M318); 2) having at least one prescription of oral corticosteroids with prednisolone-equivalent dosage ≥ 30 mg/day, methylprednisolone pulse therapy, immunosuppressive drugs (cyclophosphamide [IVCY], methotrexate, or mycophenolate mofetil), or rituximab (RTX) during hospitalization between April 2008 and April 2017; and 3) having at least 7 days of hospitalization. The observation started from the next day of discharge from the first hospitalization for RT and ended at 24 months later, the month of loss of follow-up, or April 2017. We described the frequency of hospitalization and calculated direct medical costs (per month) during the observation. We analyzed medical costs from a societal perspective. We classified reasons of hospitalization into 3 categories; intensification of treatments for AAV, AAV MT including IVCY or RTX treatments, and comorbidities (infection, cardiovascular disease [CVD], malignancy, and others) using ICD10 codes plus treatments or interventions during the hospitalization.

Results: In this study, 1,703 patients with AAV were included. The median [IQR] age was 72 [63, 79] years and 55.7% were female. The total number of hospitalization was 1,897 in 863 patients (50.7%). Among the hospitalizations, 296 hospitalization in 235 patients were categorized as intensification of treatments for AAV, 627 hospitalization in 297 patients were AAV MT, and 974 hospitalization in 572 patients were categorized as comorbidities. In the last category, infections were most frequent (220), followed by malignancy (54) and CVD (15). The mean direct medical costs per month was 20,945 EUR (1 EUR=125 JPY) in patients with hospitalization and 599 EUR in those without. Patients with hospitalization due to intensification of treatments for AAV had the highest direct medical costs (3,000 EUR), followed by those with hospitalization due to comorbidities (2,001 EUR), and those with hospitalization due to AAV MT (1,649 EUR).

Conclusion: More than half of the patients had hospitalization during MT, and hospitalization due to comorbidities were most frequent. The mean direct medical costs in patients with at least one hospitalization was approximately 3.5 times as high as that in those without hospitalization.

References:

- [1] Presse Med. 2015; 44:e251-e257
- [2] J. Rheumatol. 2015; 42:2383-91
- [3] Clin Exp Rheumatol. 2019; 137-43

Acknowledgments: This work was supported by AMED under Grant Number JP17ek0109121.

Disclosure of Interests: Ryoko Sakai Grant/research support from: Tokyo Women's Medical University (TWMU) has received unrestricted research grants for Division of Epidemiology and Pharmacoeconomics of Rheumatic Diseases from Ayumi Pharmaceutical Co. Ltd., Bristol Myers Squibb, Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp., and with which TWMU paid the salary of R.S., Eiichi Tanaka Consultant of: ET has received lecture fees or consulting fees from Abbvie, Asahi Kasei Pharma Co., Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Co., Eisai Pharmaceutical, Janssen Pharmaceutical K.K., Nippon Kayaku, Pfizer, Takeda Pharmaceutical, Taisho Toyama Pharmaceutical Co., and UCB Pharma., Speakers bureau: ET has received lecture fees or consulting fees from Abbvie, Asahi Kasei Pharma Co., Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Co., Eisai Pharmaceutical, Janssen Pharmaceutical K.K., Nippon Kayaku, Pfizer, Takeda Pharmaceutical, Taisho Toyama Pharmaceutical Co., and UCB Pharma., masayoshi harigai Grant/research support from: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., and Teijin Pharma Ltd. MH has received speaker's fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Oxford Immunotec, Pfizer Japan Inc., and Teijin Pharma Ltd. MH is a consultant for AbbVie, Boehringer-Ingelheim, Kissei Pharmaceutical Co., Ltd. and Teijin Pharma.

DOI: 10.1136/annrheumdis-2020-eular.806

AB1191

AWARENESS OF PRESCRIPTION DRUGS FOR RHEUMATOID ARTHRITIS AMONGST PATIENTS - A COMPARISON OF THE RESULTS FROM 2014 AND 2018 SURVEYS-

M. Sato¹, M. Takemura². ¹Kaizu Medical Association Hospital, Rheumatology, Kaizu City, Gifu, Japan; ²Fujita Health University, Advanced Diagnostic System Research Laboratory, Toyoake, Aichi, Japan

Background: Treatment of rheumatoid arthritis (RA) is based on drug therapy. With the increasing number of effective drugs being authorized for use and generic drugs becoming available in the market, patients with RA now have an abundance of drugs as treatment options.

Objectives: To conduct a survey of RA patients to evaluate their knowledge about the prescribed drugs, their names, and the respective categories.

Methods: In 2014 and 2018, two different surveys were done in which RA patients were interviewed regarding the name of biologics (trade name) and

other oral medications (category and trade name of anti-rheumatic drugs, steroid drugs and anti-inflammatory analgesics). The results of the two investigations are compared in this study.

Results: A total of 135 (34 men and 101 women) and 184 patients (31 men and 153 women) were interviewed in the surveys done in 2014 and 2018, respectively. In the 2014 survey, the mean age of the patients was 58.5 years (range: 25-88 years), while in the 2018 survey, the mean age of the patients was 61.0 years (range: 14-84 years). The various biologics prescribed to the patients who participated in the 2014 vs. 2018 surveys were as follows: infliximab (27 vs. 22), etanercept (11 vs. 9), adalimumab (14 vs. 16), tocilizumab (43 vs. 71), abatacept (29 vs. 46), golimumab (7 vs. 11), certolizumab-pegol (4 vs. 3), sarilumab (0 vs. 2), and tofacitinib (0 vs. 5), respectively. The number of patients who were prescribed various categories of oral medications, as stated in the 2014 vs 2018 surveys, was as follows: anti-rheumatic drugs, 104 (77.0%) vs. 131 (71.2%); steroid drugs, 36 (26.7%) vs. 44 (23.9%); and anti-inflammatory analgesics, 49 (36.3%) vs. 61 (33.2%), respectively. The number of patients that took medications without any knowledge about the drug name or its category, as reported in the 2014 vs. 2018 surveys was as follows: anti-rheumatic drugs, 24 (23.1%) vs. 42 (32.1%); steroid drugs, 11 (30.1%) vs. 24 (54.5%); and anti-inflammatory analgesics, 15 (30.6%) vs. 17 (27.9%), respectively. In the corresponding years, the number of patients who responded negatively to the question whether they knew about the trade name of the biologics prescribed to them was 15 (11.1%) and 26 (14.1%), in the 2014 and 2018 surveys, respectively. The mean age of the patients who expressed lack of knowledge with respect to the trade name of the biologics prescribed to them was 67.3 and 69.5 years old, in the 2014 and 2018 surveys, respectively; thus suggesting the impact of old age on awareness about prescribed drugs. Many of the biologics prescribed to these patients were intravenous drip formulations, and only one patient was prescribed self-administered subcutaneous injection formulation. This implied that the majority of patients who expressed lack of knowledge regarding the trade name of the biologics were administered the drug by health-care providers at the hospital.

Conclusion: Our investigation about RA patients' understanding of the trade names and category of the drugs they were administered revealed that 20 to 50% of the patients were unaware about the oral medications they were receiving. In particular, there were many patients who had misinterpreted steroidal drugs as analgesics. In addition, approximately 10% of the patients lacked an understanding of drugs that require cautious use due to their potential for causing adverse events. For those biologics administered at the hospital by health-care providers, the patients had a lack of inclination to learn the drug name. In today's era, with the emergence of generic drugs and an increase in the drug categories, it is not easy for the aging patients to understand and remember information about the prescription drugs. Hence, it is necessary to come up with measures to tackle this situation.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.1378

AB1192

THE UNDERWORLD OF DEPRESSIVE SYMPTOMS IN RHEUMATIC DISEASES: OVERLOOKED, UNRECOGNIZED OR UNPERCEIVED?

F. Ingegneri^{1,2}, T. Schioppo^{1,2}, T. Ubiali¹, V. Bollati^{2,3}, S. Ostuzzi⁴, M. Buoli^{2,5}, R. Caporali^{1,2}. ¹G Pini Hospital, Clinical Rheumatology Unit, Milan, Italy; ²Università degli Studi di Milano, Milan, Italy; ³EPiGET Lab, Milan, Italy; ⁴ALOMAR Lombard Association for Rheumatic Diseases, Milan, Italy; ⁵IRCCS Ca'Granda Policlinico, Milan, Italy

Background: The concomitant presence of depressive symptoms and rheumatic diseases (RDs) impose a considerable economic and social burden on the communities as they are associated with numerous deleterious outcomes such as increased mortality, work disability, higher disease activity and worsening physical function, higher pain levels and fatigue. Despite growing interest on depressive symptoms burden in RDs, current patient perception on this topic is unknown.

Objectives: Italian patients with RDs were invited to participate in an online study gauging the presence and the perception of depressive symptoms using the Patient Health Questionnaire (PHQ-9).

Methods: This was a cross-sectional non-profit online study to screen the presence and the perception of depressive symptoms in RDs patients. All participants gave their consent to complete the PHQ-9 and they were not remunerated. Completion was voluntary and anonymous. The PHQ-9 rates the frequency of symptoms over the past 2 weeks on a 0-3 Likert-type scale. It contains the following items: anhedonia, depressed mood, trouble sleeping, feeling tired, change in appetite, guilt or worthlessness, trouble concentrating, feeling slowed down or restless, and suicidal thoughts. Patients were stratified as: <4 not depressed, 5-9 sub-clinical or mild depression, 10-14 moderate depression, 15-19 moderately severe depression and 20-27 severe depression. The survey was disseminated by ALOMAR (Lombard Association for Rheumatic Diseases) between June and October 2019.